Mesoblast Limited (MESO) Q4 2024 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Mesoblast Limited.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.009 -- 00:00:05.252 Thank you, operator. And I'm very pleased to welcome everybody to the financial results 00:00:05.252 -- 00:00:09.924 and operational update for the year end of June 30th, 2024. 00:00:10.755 -- 00:00:12.516 With me today, 00:00:12.516 -- 00:00:18.000 Chief Financial Officer Andrew Schapanel and one of our members of the board, 00:00:18.000 -- 00:00:23.963 Dr. Philip Krause, formerly Deputy Director of the Vaccine Division of 00:00:23.963 -- 00:00:26.563 FDA's CBER. 00:00:28.024 -- 00:00:33.227 I'm very pleased to report that in the past six months, Miseblast has 00:00:33.227 -- 00:00:36.248 made tremendous progress, 00:00:36.248 -- 00:00:41.331 and we've built great momentum in our relationships with the 00:00:41.331 -- 00:00:47.633 FDA on each of our three lead products. We are now 00:00:47.974 -- 00:00:52.937 in a strong position to have our first potential 00:00:52.937 -- 00:00:58.354 product approved by the FDA and planning for a go-to-market strategy 00:00:58.354 -- 00:01:01.375 our first commercial launch. 00:01:01.536 -- 00:01:05.357 We could go now to the slide deck, please. 00:01:07.439 -- 00:01:11.520 Starting with slide four. 00:01:12.141 -- 00:01:17.264 We're a global leader in allogeneic cellular medicines for inflammatory diseases 00:01:17.264 -- 00:01:22.447 and have established a leading position with intellectual capital 00:01:22.447 -- 00:01:25.108 with over 1,000 patents 00:01:25.108 -- 00:01:30.313 granted or filed across all the major jurisdictions. 00:01:32.295 -- 00:01:33.816 Slide 00:01:33.816 -- 00:01:35.277 five. 00:01:35.277 -- 00:01:40.559 Our platform technology demonstrates a shared mechanism of action across 00:01:40.559 -- 00:01:43.019 all of our products. 00:01:43.620 -- 00:01:48.682 The mesenchymal ...